Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - pazopanib hydrochloride, quantity: 433.4 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc). votrient is indicated for the treatment of patients with advanced (unresectable and/or metastatic) soft tissue sarcoma (sts) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment. the phase iii trial population excluded patients with gastrointestinal stromal tumour (gist) or adipocytic soft tissue sarcoma.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - pazopanib (pazopanib hydrochloride) - tablet - 400mg - pazopanib (pazopanib hydrochloride) 400mg - antineoplastic agents

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pazopanib hydrochloride 216,7 mg - eq. pazopanib 200 mg - film-coated tablet - pazopanib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - pazopanib hydrochloride 216,7 mg - eq. pazopanib 200 mg - film-coated tablet - pazopanib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - pazopanib hydrochloride 216,7 mg - eq. pazopanib 200 mg - film-coated tablet - pazopanib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - pazopanib hydrochloride 216,7 mg - eq. pazopanib 200 mg - film-coated tablet - pazopanib

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - pazopanib hydrochloride -

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines inc. - pazopanib (as hydrochloride) - film-coated tablet - 200 mg

Philippines - English - FDA (Food And Drug Administration)

novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - pazopanib (as hydrochloride) - film-coated hydrochloride - 200 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - pazopanib hydrochloride 433.4mg equivalent to pazopanib 400 mg - film coated tablet - 400 mg - active: pazopanib hydrochloride 433.4mg equivalent to pazopanib 400 mg excipient: hypromellose macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 povidone purified water   sodium starch glycolate titanium dioxide - renal cell carcinoma (rcc) pazopanib (teva) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc).